Peptides for Hepatitis B: Novel Antiviral Strategies

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptide-based therapies are emerging as novel antiviral strategies for Hepatitis B, aiming to inhibit viral replication and modulate immune responses. These targeted interventions offer potential to improve treatment outcomes and achieve functional cure in HBV patients.

Peptides for Hepatitis B: Advancing Towards a Functional Cure

Hepatitis B virus (HBV) infection remains a significant global health challenge, affecting millions and leading to chronic liver disease, cirrhosis, and hepatocellular carcinoma. Current antiviral therapies can suppress viral replication but rarely achieve a functional cure, necessitating lifelong treatment for many patients. The development of peptide-based therapies represents a promising frontier in the quest for more effective and potentially curative treatments for Hepatitis B, focusing on direct antiviral action and immune system modulation.

Peptide-Based Strategies Against Hepatitis B

Peptides are being explored for their ability to interfere with various stages of the HBV life cycle and to enhance the host's immune response against the virus.

1. Direct Antiviral Peptides and Peptoids

• Disrupting Viral Particles: Some peptoids, such as TM19, have shown potent antiviral effects by directly disrupting HBV viral particles, preventing infection in cell cultures [4]. This offers a novel mechanism of action compared to traditional antivirals.
• Targeting Viral Proteins: Peptides can be designed to target crucial HBV proteins. For instance, certain peptides have been identified that disrupt the interaction between the Hepatitis B core protein (HBc) and the HBV surface protein (L-HBs), which is essential for viral assembly and release [11].
• Blocking Entry: Peptides derived from the preS1 region of the HBV large surface antigen, like 4B10, can efficiently inhibit HBV entry into host cells by binding to the N-terminal half of preS1 [14]. This prevents the virus from establishing an infection.

2. Immune Modulating Peptides

• Therapeutic Vaccines: Peptide-based therapeutic vaccines aim to stimulate a robust and specific immune response against HBV. For example, a hepatitis B virus-derived peptide combined with HBsAg has shown potential as a therapeutic vaccine [1]. Synthetic long peptides (SLP®) containing both CD4+ and CD8+ T cell epitopes are also being investigated to induce broad multifunctional T-cell responses [8].
• Targeting Immune Checkpoints: Immunotherapy approaches are exploring peptides that target immune system components. For instance, identifying stable peptides like Env371-379 L6I that effectively trigger T-cell activation by targeting HLA-E could lead to new ways to treat chronic Hepatitis B [5].
• Thymus-Derived Peptides: Immune-active peptides derived from the thymus have been evaluated for their role in treating viral chronic hepatitis, suggesting a broader immune-enhancing effect [2].

Challenges and Future Directions

While peptide-based therapies hold immense promise, challenges remain, including optimizing peptide stability, delivery, and ensuring a sustained antiviral effect without significant side effects. No peptide-based therapy has yet achieved a functional cure as a standalone treatment [3], highlighting the need for combination therapies.

Practical Takeaway

If you are living with Hepatitis B, it's essential to work closely with your hepatologist to manage your condition. While peptide therapies are still largely in the research phase, they represent a rapidly evolving area. Discussing ongoing clinical trials and novel therapeutic approaches with your doctor can help you stay informed about potential future treatment options that may offer a path towards a functional cure.

References

[1] Li, Y., et al. (2023). A hepatitis B virus-derived peptide combined with HBsAg exerts an enhanced immune response and antiviral effect in mice. Frontiers in Immunology, 14, 1198906. https://pmc.ncbi.nlm.nih.gov/articles/PMC10272379/
[2] Pisi, E., et al. (1996). Thymus-derived peptides in the treatment of viral chronic hepatitis. Immunopharmacology and Immunotoxicology, 18(4), 579-592. https://pubmed.ncbi.nlm.nih.gov/9030468/
[3] RethinkPeptides. (2026). Peptide Approaches to Hepatitis B Cure Research. https://rethinkpeptides.com/articles/peptide-based-approaches-to-hepatitis-b-cure-research
[4] Li, Y., et al. (2024). Antiviral effect of peptoids on hepatitis B virus infection in cell culture. Antiviral Research, 221, 105769. https://www.sciencedirect.com/science/article/abs/pii/S0166354224000299
[5] Contagion Live. (2024). New Immunotherapy Approach Targets Immune System to Treat Chronic Hepatitis B. https://www.contagionlive.com/view/new-immunotherapy-approach-targets-immune-system-to-treat-chronic-hepatitis-b
[8] Zhang, Y., et al. (2023). Induction of broad multifunctional CD8+ and CD4+ T cells responses by a novel therapeutic vaccine for chronic hepatitis B. Frontiers in Immunology, 14, 1163118. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1163118/full
[11] Khayenko, V., et al. (2025). Induction of hepatitis B core protein aggregation targeting the N-terminal domain. eLife, 14, RP98827. https://elifesciences.org/articles/98827
[14] Ye, X., et al. (2016). Efficient Inhibition of Hepatitis B Virus Infection by a preS1-derived peptide. Scientific Reports, 6, 29391. https://www.nature.com/articles/srep29391